ArrayExpress Uploader04023proliferativewtM980513T2aN3M1cLymph node metastasis iliacalV600EproliferativeQ61RM010817TxN1bM1cSkin metastasis left upper armwtproliferativeQ61LM050829T3aN3M0Skin metastasis retrauricular rightwtproliferativewtM000921TxNxM1cEpigastric metastasisV600EproliferativeG12DM080423T3bN1aM1aLymph node metastasis hepatoduodenalwtproliferativewtM080326T4bN2aM0Primary plantarV600EinvasivewtM080306T2N1bM0Primary capillitiumwtinvasivewtM061103T4N1bM0Skin metastasis capillitiumwtinvasivewtM060125TxNxM1cSkin metastasis scapulaV600EinvasivewtM010119T2bN3M0Skin metastasis shoulderL597SinvasivewtM081008T1aN0M0Primary facewtinvasivewtM080307T4N2M1cSoft tissue metastasis axillawtarrayexpress_sid4Recent trials with MAPK inhibitors have shown promising results in many patients with metastatic melanoma; however, nearly all responding...21176117E-GEOD-28335/profile/8773/arrayexpressuploader612celldiseasemelanomametastatic melanomaDec.12, 2014Falsemelanoma-cell-culture-phenotypesE-GEOD-28335_A-AFFY-44Melanoma cell culture phenotypesSep.16, 2014Recent trials with MAPK inhibitors have shown promising results in many patients with metastatic melanoma; however, nearly all responding patients experience disease relapse. We describe here how melanoma cells respond to MAPK inhibition in a phenotype-specific manner, suggesting that slow cycling invasive phenotype cells provide a treatment-resistant pool from which disease relapse may be derived. The implication is that while MAPK inhibition may successfully treat proliferating cells, another cell population needs to be addressed at the same time. 12 sampleshttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28335humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-28335/samples/